{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Reporting of the relative amount of patients for whom such sdAb could be successfully obtained","groups":[{"description":"Only 1 arm/group in this trial","id":"OG000","title":"Patients With a Clinically Suspected or Pathologically Confirmed Multiple Myeloma."}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Out of 10 patients included, three patients with confirmed surface Ig expression were selected for sdAb generation.","reportingStatus":"POSTED","timeFrame":"Within 2 years after study completion","title":"Fraction of Patients (n=3) for Whom a sdAb Could be Generated That Binds to the Idiotype of the Paraprotein.","type":"PRIMARY","unitOfMeasure":"Participants"}